Spotlight

Aimmune Therapeutics is engaged in the development of advanced treatments for life-threatening food allergies. The latest investment brings Nestlé’s total investment in the drug developer for food allergies

The priority review for Lynparza (olaparib) is for the maintenance treatment of such patients who had shown complete or partial response after first-line standard platinum-based chemotherapy. The FDA

GS-9674 is an investigational, selective and non-steroidal agonist of the (FXR), which is a nuclear hormone receptor that is highly expressed in the gastrointestinal tract and liver. FXR

The Switzerland-based Covis Pharma will also make conditional sales-related payments for the three over-the-counter (OTC) drugs of up to $21m over four years from 2019. AstraZeneca global product

GKT831 recorded high statistical significance following six weeks of treatment, said the French biotech company. The 24-week placebo-controlled trial is being held across multiple countries in 111 PBC

IPI-549 is an oral immuno-oncology development candidate, which is designed to selectively inhibit phosphoinositide-3-kinase (PI3K)-gamma. It is claimed to be the only investigational PI3K-gamma inhibitor in clinical development.

The approval allows more patients to be treated with Venclyxto in the second-line setting while giving healthcare providers the ability to prescribe the drug to a larger population

The proceeds from the new funding round will be used by Stoke Therapeutics to advance its pipeline of antisense oligonucleotide medicines, designed for the treatment of severe genetic

Cerevel Therapeutics has secured $350m funding from funds affiliated with Bain Capital Private Equity and Bain Capital Life Sciences. They have also committed to provide further capital if